We first addressed the question on whether the combination of both biomarkers, circulating transcripts of MACC1 and of S100A4, might improve the prognostic value of MACC1 alone in the cohort of newly diagnosed CRC patients. This evidence concerns the gene S100A4 and colorectal carcinoma.